Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5) > Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5):622-31



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


GUIDELINES   Free accessfree

Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5):622-31

DOI: 10.23736/S0392-0488.19.06399-5


lingua: Inglese

Androgenetic alopecia in women and men: Italian guidelines adapted from European Dermatology Forum/European Academy of Dermatology and Venereology guidelines

Aurora ALESSANDRINI 1, Michela STARACE 1, Roberto D’OVIDIO 2, Lucia VILLA 3, Alfredo ROSSI 4, Teodora R. STAN 5, Piergiacomo CALZAVARA-PINTON 6, Bianca M. PIRACCINI 1

1 Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 2 S. Camillo Hospital, Monopoli, Bari, Italy; 3 Private Practitioner, San Benedetto del Tronto, Ascoli Piceno, Italy; 4 Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy; 5 Private Practitioner, Padua, Italy; 6 Department of Dermatology, University of Brescia, Brescia, Italy

Androgenetic alopecia (AGA) is the most common form of alopecia, affecting up to 80% of men and 50% of women in the course of their life. AGA is caused by a progressive reduction in the diameter, length and pigmentation of the hair, resulting from the effects of the testosterone metabolite dihydrotestosterone (DHT) on androgen-sensitive hair follicles. Clinical presentation is different in men and women. Trichoscopy is used routinely in patients with androgenetic alopecia, for diagnosis and differential diagnosis with other diseases, allowing staging of severity and monitoring the progress of the disease and the response to treatment. Medical treatment of AGA includes topical minoxidil, antiandrogen agents, 5-alpha reductase inhibitors and many other options. This guideline for the treatment of androgenetic alopecia has been developed by an Italian group of experts taking into account the Italian pharmacological governance. The article is adapted from the original of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S3 level).

KEY WORDS: Alopecia; Therapy; Guidelines

inizio pagina